Aft Pharmaceuticals Ltd
AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, pain management, skin care, vitamins, supplements, gastrointestinal, … Read more
Aft Pharmaceuticals Ltd (AFP) - Total Liabilities
Latest total liabilities as of September 2025: AU$73.04 Million AUD
Based on the latest financial reports, Aft Pharmaceuticals Ltd (AFP) has total liabilities worth AU$73.04 Million AUD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Aft Pharmaceuticals Ltd - Total Liabilities Trend (2013–2025)
This chart illustrates how Aft Pharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Aft Pharmaceuticals Ltd Competitors by Total Liabilities
The table below lists competitors of Aft Pharmaceuticals Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Regis Corporation Common Stock
NYSE:RGS
|
USA | $399.61 Million |
|
STPCF
OTCGREY:STPCF
|
USA | $11.25 Million |
|
Senzime AB (publ)
OTCGREY:SNZZF
|
USA | $63.82 Million |
|
Freightos Limited Ordinary shares
NASDAQ:CRGO
|
USA | $22.40 Million |
|
Verde Resources Inc
OTCQB:VRDR
|
USA | $1.48 Million |
|
Muhibbah Engineering M Bhd
KLSE:5703
|
Malaysia | RM1.60 Billion |
|
Action SA
WAR:ACT
|
Poland | zł314.76 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Aft Pharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.74 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aft Pharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aft Pharmaceuticals Ltd (2013–2025)
The table below shows the annual total liabilities of Aft Pharmaceuticals Ltd from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | AU$72.74 Million | -6.10% |
| 2024-03-31 | AU$77.46 Million | +3.57% |
| 2023-03-31 | AU$74.80 Million | +15.04% |
| 2022-03-31 | AU$65.02 Million | -5.15% |
| 2021-03-31 | AU$68.54 Million | -1.80% |
| 2020-03-31 | AU$69.80 Million | +19.30% |
| 2019-03-31 | AU$58.50 Million | +18.76% |
| 2018-03-31 | AU$49.26 Million | +26.78% |
| 2017-03-31 | AU$38.85 Million | +4.80% |
| 2016-03-31 | AU$37.07 Million | +18.86% |
| 2015-03-31 | AU$31.19 Million | +39.13% |
| 2014-03-31 | AU$22.42 Million | +25.20% |
| 2013-03-31 | AU$17.91 Million | -- |